Zydus Lifesciences Limited has informed the Exchange regarding a press release dated April 20, 2023, titled "Zydus receives final approval from the USFDA for Metoprolol Tartrate Tablets USP, 25 mg, 50 mg, and 100 mg".
Press Release Apr 20 2023
Filed with NSE · · 2 pages · English
Summary by 6ix AI
Zydus Lifesciences Limited has issued a press release announcing that it received final approval from the USFDA for Metoprolol Tartrate Tablets in various dosages. This medication is used to treat high blood pressure and other heart-related conditions. The tablets will be manufactured at the company's facility in Baddi, Himachal Pradesh. The press release aims to inform investors and exchange members about this significant approval.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Release
Zydus Lifesciences Limited on 6ix
Earlier from Zydus Lifesciences
- Press Release Apr 19 2023
- Press Release Apr 18 2023
- Press Release Apr 15 2023
- Press Release Apr 11 2023
- Press Release Apr 10 2023
Later from Zydus Lifesciences
- Zydus Lifesciences Limited Press Release Apr 24 2023
- Press Release Apr 25 2023
- Press Release May 04 2023
- Press Release May 10 2023
- Press Release May 17 2023
Follow Zydus Lifesciences into a list and get an email when it puts out news.
Follow Zydus Lifesciences